Whalesbook
Q4 mein toh Niva Bupa ne dhamaal machaya!
Dekho yaar, Niva Bupa Health Insurance ne Q4 FY26 mein ekdum zabardast performance dikhaya hai. Unka gross written premium 38.5% badh kar ₹2,880 crore ho gaya, aur net profit toh 67.5% uchhal kar ₹345 crore par pahunch gaya! Ye sab unke naye products aur distribution channels ki wajah se ho raha hai. Company ka plan hai ki aage bhi 5 saal tak 23-25% per year grow karenge, jo overall market se kaafi zyada hai.
Par ye valuation aur profitability ka kya scene hai?
Sabse bada sawaal toh yahi hai ki stock ka valuation bahut hi high hai. Iska P/E ratio 114.81 par hai, jabki peers jaise Star Health ka 39.1 se 61.9, ICICI Lombard ka 31-34, aur HDFC ERGO ka 53.56 ke aas-paas hai. Analysts isko thoda 'risky' bhi bol rahe hain.
Phir aata hai profitability ka issue. FY29 tak combined ratio ko 100% se neeche laana hai, par abhi yeh 101.4% par hai. Company keh rahi hai ki renewal business badha kar aur costs kam karke isko control karenge. Lekin, poore FY25-26 ke liye company ka profit actually 39% gir gaya tha, ₹130.8 crore par aa gaya. Stock price ki baat karein toh ₹85.51 par hai aur pichhle saal mein yeh 6.88% gira bhi hai. Market cap filhal ₹15,789.6 crore ke aas-paas hai. Aur haan, ab tak koi dividend bhi nahi mila hai investors ko.
Market position aur Naye Rules
Indian health insurance market toh mast grow kar raha hai, aur Niva Bupa ka standalone private insurers mein share 17.59% hai (total health insurance mein 5.31%). IRDAI bhi naye rules laa raha hai jisse market aur bhi badhega, par insurers ke liye risk manage karna thoda mushkil ho sakta hai.
Is sab ke beech, ek analyst ne 'BUY' rating ke saath ₹90 ka target bhi diya hai, unko lagta hai ki yeh competitors se zyada earnings grow karega.